) has been revised to $6.12 / share. This is an increase of 100.00% from the prior estimate of $3.06 dated September 10, 2025. The price target is an average of many targets provided by analysts. The ...

Citius Oncology, Inc. focuses on the development and commercialization of innovative targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment ...

Institutional Holdings information is filed by major institutions on form 13-F with the Securities and Exchange Commission. Major institutions are defined as firms or individuals that exercise ...

Citius Oncology Inc. (NASDAQ:CTOR) is one of the most undervalued penny stocks to buy right now. On February 11, Citius Oncology entered into an exclusive distribution agreement with Uniphar to expand ...

Fintel reports that on September 23, 2025, Maxim Group upgraded their outlook for Citius Oncology (NasdaqCM:CTOR) from Hold to Buy. As of September 13, 2025, the average one-year price target for ...

Find the latest Citius Oncology, Inc. (CTOR) stock quote, history, news and other vital information to help you with your stock trading and investing.